Press release: dupixent approved in the eu as the first and only medicine for young children with eosinophilic esophagitis

Dupixent approved in the eu as the first and only medicine for young children with eosinophilic esophagitis approval based on phase 3 data showing significantly more children aged one to 11 years on dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year dupixent is the first-ever medicine in the eu indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth is crucial paris and tarrytown, ny, november 6, 2024. the european medicines agency has approved dupixent (dupilumab) to treat eosinophilic esophagitis (eoe) in children as young as one year of age.
REGN Ratings Summary
REGN Quant Ranking